论文部分内容阅读
目的:比较雷贝拉唑与奥美拉唑对幽门螺杆菌(Helicobacter pylori,以下简称Hp)相关性胃溃疡患者的临床疗效及其对血清胃泌素和生长抑素的影响。方法:选取2015年1月—2017年3月期间医院收治的Hp相关性胃溃疡患者78例病例资料,将其随机分为Ⅰ组和Ⅱ组(每组39例);两组患者在常规治疗基础上Ⅰ组患者加用奥美拉唑肠溶胶囊治疗,Ⅱ组患者给予雷贝拉唑肠溶胶囊治疗,比较两组患者用药后的临床疗效及其对Hp相关性胃溃疡患者的临床疗效及其对血清胃泌素(GAS)和生长抑素(SS)水平的影响。结果:Ⅰ组患者治疗后的总有效率为89.74%与Ⅱ组为94.87%,经组间比较其差异无统计学意义(P>0.05);治疗前,两组患者GAS和SS测得值值经比较其差异均无统计学意义(P>0.05);治疗后,两组患者的GAS测得值小于治疗前(P<0.05),SS值大于治疗前(P<0.05);Ⅱ组患者的GAS测得值小于Ⅰ组(P<0.05),SS值大于Ⅰ组(P<0.05)。结论:雷贝拉唑用于治疗Hp相关性胃溃疡患者的临床疗效优于奥美拉唑,且有效改善了GAS和SS水平值。
OBJECTIVE: To compare the clinical efficacy of rabeprazole and omeprazole in patients with gastric ulcer associated with Helicobacter pylori (Hp) and its effect on serum gastrin and somatostatin. Methods: A total of 78 patients with Hp-related gastric ulcer admitted from January 2015 to March 2017 in our hospital were selected and randomly divided into group Ⅰ and group Ⅱ (39 cases in each group). Patients in both groups were treated with routine treatment Based on the group Ⅰ patients plus omeprazole enteric-coated capsules, patients in group Ⅱ were given rabeprazole enteric-coated capsules, the clinical efficacy of the two groups of patients after treatment and its clinical efficacy of Hp-related gastric ulcer patients And its effect on serum gastrin (GAS) and somatostatin (SS) levels. Results: The total effective rate after treatment in group Ⅰ was 89.74% and in group Ⅱ 94.87%, there was no significant difference between the two groups (P> 0.05). Before treatment, the measured values of GAS and SS After treatment, the GAS values of the two groups were less than those before treatment (P <0.05), and the SS values were greater than those before treatment (P <0.05); the patients in group Ⅱ GAS measured value was less than Ⅰ group (P <0.05), SS value was greater than Ⅰ group (P <0.05). Conclusion: Rabeprazole is superior to omeprazole in the treatment of patients with Hp-related gastric ulcer, and has an effect of improving the levels of GAS and SS.